The impact of Mir-9 regulation in normal and malignant hematopoiesis

Main Article Content

Abbas Khosravi (1), Shaban Alizadeh (2), Arsalan Jalili (3), Reza Shirzad (4), Najmaldin Saki (5*)

1 Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran, Islamic Republic of.
2 Hematology Department, Allied Medical School, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of.
3 Department of Stem Cells and Developmental Biology at Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran, Islamic Republic of.
4 WHO Collaborating Center for Reference and Research on Rabies, Pasteur Institute of Iran, Tehran, Iran, Islamic Republic of.
5 Thalassemia & Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of.
(*) Corresponding Author:
Najmaldin Saki


MicroRNA-9 (MiR-9) dysregulation has been observed in various cancers. Recently, MiR-9 is considered to have a part in hematopoiesis and hematologic malignancies. However, its importance in blood neoplasms is not yet well defined. Thus, this study was conducted in order to assess the significance of MiR-9 role in the development of hematologic neoplasia, prognosis, and treatment approaches. We have shown that a large number of MiR-9 targets (such as FOXOs, SIRT1, CCND1, ID2, CCNG1, Ets, and NFkB) play essential roles in leukemogenesis and that it is overexpressed in different leukemias. Our findings indicated MiR-9 downregulation in a majority of leukemias. However, its overexpression was reported in patients with dysregulated MiR-9 controlling factors (such as MLLr). Additionally, prognostic value of MiR-9 has been reported in some types of leukemia. This study generally emphasizes on the critical role of MiR-9 in hematologic malignancies as a prognostic factor and a therapeutic target.

Downloads month by month


Download data is not yet available.

Article Details

How to Cite
Khosravi, A., Alizadeh, S., Jalili, A., Shirzad, R., & Saki, N. (2018). The impact of Mir-9 regulation in normal and malignant hematopoiesis. Oncology Reviews, 12(1).